Bristol Myers Squibb将提供nivolumab。 Nivolumab是一种免疫检查点抑制剂，旨在阻止癌细胞上的PD-L1蛋白与PD-1结合，增强T细胞功能，从而提高抗肿瘤反应。

Get real-time updates on Bristol-Myers Squibb Company Common Stock (BMY) stock quotes, trades, and more. Make informed investments with Nasdaq.